PriceCPThompsonPW. The role of biochemical tests in the screening and monitoring of osteoporosis. Ann Clin Biochem1995; 32: 244–60
2.
UebelhartDSchlemmerAJohansenJSGineytsEChristiansenCDelmasPD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab1991; 72: 367–73
3.
SchlemmerAHassagerCJensenSBChristiansenC. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab1992; 74: 476–80
4.
VasikaranSDMcCloskeyEVKahnSKanisJA. Intra-individual variation in fasting urinary calcium-and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients. Ann Clin Biochem1994; 31: 272–6
5.
SeyedinSMKungVTDaniloffYNHesleyRPGomezBNielsenLA. Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Miner Res1993; 8: 635–41
6.
ColwellARussellRGGEastellR. Factors affecting the assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest1993; 23: 341–9
7.
HansonDAWeisMAEBollenAMMaslanSLSingerFREyreDR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res1992; 7: 1251–8
8.
GertzBJShaoPHansonDAQuanHHarrisSTGenantHK. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res1994; 9: 135–42
